Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 催眠药 索拉非尼 肝细胞癌 内科学 安慰剂 临床终点 肝硬化 肿瘤科 胃肠病学 肝癌 癌 随机对照试验 癌症 外科 病理 替代医学
作者
Andrew Xiuxuan Zhu,Yoon‐Koo Kang,Chia‐Jui Yen,Richard S. Finn,Peter R. Galle,Josep Maria Llovet,Eric Assénat,Giovanni Brandi,Marc Pracht,Ho Yeong Lim,Kun‐Ming Rau,Kenta Motomura,Izumi Ohno,Philippe Merle,Bruno Daniele,Dong Bok Shin,Guido Gerken,Christophe Borg,Jean‐Baptiste Hiriart,Takuji Okusaka
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:20 (2): 282-296 被引量:1834
标识
DOI:10.1016/s1470-2045(18)30937-9
摘要

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433.Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8-4·4] vs 2·8 months [1·6-2·9]; HR 0·799 [95% CI 0·545-1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639-1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma.Eli Lilly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
大气大侠完成签到,获得积分10
刚刚
柔叶完成签到,获得积分10
刚刚
felix完成签到,获得积分10
刚刚
Diane丶凯完成签到,获得积分10
1秒前
等待蓝天完成签到,获得积分10
1秒前
完美世界的应助被君仪采纳,获得10
1秒前
暮时发布了新的文献求助10
1秒前
summer发布了新的文献求助10
1秒前
魏芸芸发布了新的文献求助10
2秒前
Sky我的小清新完成签到,获得积分10
2秒前
lululu完成签到,获得积分10
2秒前
露露完成签到,获得积分10
2秒前
Brian完成签到,获得积分20
2秒前
NiLou发布了新的文献求助10
2秒前
CodeCraft的应助被阿芙洛蒂德采纳,获得10
2秒前
3秒前
科研新牛马完成签到,获得积分10
3秒前
小学三年级完成签到,获得积分10
4秒前
尉迟三颜完成签到,获得积分10
4秒前
协奏曲发布了新的文献求助10
4秒前
shawn_89完成签到,获得积分10
4秒前
4秒前
搜集达人的应助被芋头采纳,获得10
4秒前
4秒前
大模型的应助被LQ采纳,获得10
5秒前
5秒前
za发布了新的文献求助10
5秒前
草莓燕麦大酸奶完成签到,获得积分10
5秒前
5秒前
可爱的函函的应助被Mjj采纳,获得10
5秒前
6秒前
刘能能完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
boyis完成签到,获得积分10
7秒前
脑洞疼的应助被合适的咖啡采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182513
求助须知:如何正确求助?哪些是违规求助? 9571996
关于积分的说明 21821383
捐赠科研通 7778989
什么是DOI,文献DOI怎么找? 3433670
关于科研通互助平台的介绍 2557827
邀请新用户注册赠送积分活动 2479731